Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - factor viii, quantity: 250 iu - injection, solution - excipient ingredients: water for injections - human coagulation factor viii is indicated for the treatment and prophylaxis of bleeding associated with factor viii deficiency due to haemophilia a.

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - factor viii, quantity: 500 iu - injection, solution - excipient ingredients: water for injections - human coagulation factor viii is indicated for the treatment and prophylaxis of bleeding associated with factor viii deficiency due to haemophilia a.

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - factor viii, quantity: 250 iu - injection, solution - excipient ingredients: water for injections - human coagulation factor viii is indicated for the treatment and prophylaxis of bleeding associated with factor viii deficiency due to haemophilia a.

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - factor viii, quantity: 500 iu - injection, solution - excipient ingredients: water for injections - human coagulation factor viii is indicated for the treatment and prophylaxis of bleeding associated with factor viii deficiency due to haemophilia a.

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - factor viii, quantity: 500 iu - injection, solution - excipient ingredients: water for injections - human coagulation factor viii is indicated for the treatment and prophylaxis of bleeding associated with factor viii deficiency due to haemophilia a.

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - factor viii, quantity: 500 iu - injection, solution - excipient ingredients: water for injections - human coagulation factor viii is indicated for the treatment and prophylaxis of bleeding associated with factor viii deficiency due to haemophilia a.

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - anti-d rho immunoglobulin -

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - factor ix, quantity: 1000 iu - injection, diluent for - excipient ingredients: water for injections - monofix-vf is indicated for the treatment of haemorrhages, for use in surgery, and as prophylaxis in patients with haemophilia b. monofix-vf is not indicated for the treatment of factor ii, vii or x deficiencies because it does not contain therapeutic levels of these coagulation factors. monofix-vf is not indicated for the treatment of haemophilia a patients with factor viii inhibitors.

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - factor ix, quantity: 500 iu - injection, diluent for - excipient ingredients: water for injections - monofix-vf is indicated for the treatment of haemorrhages, for use in surgery, and as prophylaxis in patients with haemophilia b. monofix-vf is not indicated for the treatment of factor ii, vii or x deficiencies because it does not contain therapeutic levels of these coagulation factors. monofix-vf is not indicated for the treatment of haemophilia a patients with factor viii inhibitors.

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - zoster immunoglobulin, quantity: 160 mg/ml - injection, solution - excipient ingredients: glycine - zoster immunoglobulin-vf is indicated for prophylaxis against varicella in patients who meet all four of the criteria listed below: 1. one of the following underlying illnesses or conditions: a. neoplastic disease (leukaemia or lymphoma) b. congenital or acquired immunodeficiency c. immunosuppressive therapy with steroids or antimetabolites. 2. one of the following types of exposure to chickenpox or shingles patients: a. household contact b. playmate contact (> 1 hour play indoors) c. hospital contact (in same 2 to 4 bedroom or adjacent beds in a large ward) d. newborn contact (newborn of mother who had onset of chickenpox < 5 days before delivery or within 48 hours after delivery) e. premature infant (greater than or equal to 28 weeks gestation) whose mother lacks a prior history of chickenpox f. premature infant (< 28 weeks gestation or less than or equal to 1000 g) regardless of maternal history. 3. negative or unknown prior history of chickenpox. 4. if zoster immunoglobulin-vf can be administered within 96 hours after exposure. zoster immunoglobulin-vf, normal immunoglobulin-vf (immunoglobulin for intramuscular use) or plasma are of no value in the treatment of established varicella or zoster infection. high levels of circulating antibody do not prevent dissemination of infection. zoster immunoglobulin-vf is not indicated for prophylactic use in immunodeficient children or adults when there is a history of varicella, unless the patient's immunosuppressed status is that which is associated with bone marrow transplantation.